Last reviewed · How we verify
NCT06287502
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
NA trial testing β-hydroxy β-methylbutyrate (HMB) in Sarcopenia in 13 participants. Completed in 30 June 2024.
30 April 2024
Quick facts
| Lead sponsor | Kowloon Hospital, Hong Kong |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 9 September 2022 |
| Primary completion | 30 April 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- β-hydroxy β-methylbutyrate (HMB)
- Resistance, aerobic, flexibility and balance exercise training
Conditions studied
- Sarcopenia — all drugs for Sarcopenia →
- Osteoporosis — all drugs for Osteoporosis →
Sponsor
Kowloon Hospital, Hong Kong
Who can join
Eligibility, any sex, with Sarcopenia or Osteoporosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective parallel group, double-blinded randomized controlled trial. Subjects are randomized into two groups - the intervention group and waitlist control group. Subjects received resistance, aerobic, flexibility and balance exercise training; and nutritional supplement containing β-hydroxy β-methylbutyrate (HMB). The intervention group would first receive the intervention during the 12-week study period. Meanwhile, the waitlist control group would receive 12 weeks of conventional care. After the study period, they would receive the same intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06287502
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcopenia
Currently open trials in the same condition.
- NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
- NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting
Other Kowloon Hospital, Hong Kong trials
Trials by the same sponsor.
- NCT05688150 — Prevalence and Associated Factors of Sarcopenia Among Elderly Patients in Osteoporosis Clinic · completed
- NCT05159635 — Combining Active Living Programme (ALP) With Home-Use Wearable Technical Aids (WTA) · NA · completed
- NCT03093142 — The Treatment Effectiveness of Combined tDCs and Neurofeedback (NF) for Patients With Cognitive Deficits After Stroke · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06287502 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kowloon Hospital, Hong Kong
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06287502.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing